Portal de Periódicos da CAPES

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

2022; Nature Portfolio; Volume: 19; Issue: 6 Linguagem: Inglês

10.1038/s41571-022-00610-8

1759-4782

Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, John B.A.G. Haanen, Bernhard Wörmann, Samra Turajlic, Marie von Lilienfeld‐Toal,

COVID-19 Clinical Research Studies

Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became available. We also highlight critical points that might affect vaccine efficacy in patients with cancer in the future. Vaccination against COVID-19 confers robust protection from severe disease. However, the extent to which this applies to patients with cancer remains uncertain given that these patients were excluded from most of the pivotal studies. In this Review, the authors provide an overview of the efficacy and immunogenicity of COVID-19 vaccines in patients with cancer, and discuss alternatives to vaccination for those who might be unable to develop a proficient immune response following vaccination.